Your browser doesn't support javascript.
loading
A phase I study of the HDM2 antagonist SAR405838 combined with the MEK inhibitor pimasertib in patients with advanced solid tumours.
de Weger, Vincent A; de Jonge, Maja; Langenberg, Marlies H G; Schellens, Jan H M; Lolkema, Martijn; Varga, Andrea; Demers, Brigitte; Thomas, Koruth; Hsu, Karl; Tuffal, Gilles; Goodstal, Samantha; Macé, Sandrine; Deutsch, Eric.
Afiliação
  • de Weger VA; Department of Clinical Pharmacology, The Netherlands Cancer Institute, Amsterdam, The Netherlands. v.deweger@gmail.com.
  • de Jonge M; Department of Medical Oncology, Erasmus MC/Daniel den Hoed Cancer Center, Rotterdam, The Netherlands.
  • Langenberg MHG; UMC Utrecht Cancer Center, Utrecht, The Netherlands.
  • Schellens JHM; Department of Clinical Pharmacology, The Netherlands Cancer Institute, Amsterdam, The Netherlands.
  • Lolkema M; Utrecht Institute for Pharmaceutical Sciences, Utrecht, The Netherlands.
  • Varga A; Department of Medical Oncology, Erasmus MC/Daniel den Hoed Cancer Center, Rotterdam, The Netherlands.
  • Demers B; UMC Utrecht Cancer Center, Utrecht, The Netherlands.
  • Thomas K; Gustave Roussy, INSERM 1030, F-94805, Villejuif, France.
  • Hsu K; Sanofi Oncology, Vitry-sur-Seine, France.
  • Tuffal G; Sanofi Oncology, Cambridge, USA.
  • Goodstal S; Sanofi Oncology, Cambridge, USA.
  • Macé S; Sanofi R&D, Montpellier, France.
  • Deutsch E; EMD Serono Research & Development Institute, Inc., Billerica, USA.
Br J Cancer ; 120(3): 286-293, 2019 02.
Article em En | MEDLINE | ID: mdl-30585255

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Compostos de Espiro / Niacinamida / Proteínas Proto-Oncogênicas c-mdm2 / Indóis / Neoplasias Idioma: En Ano de publicação: 2019 Tipo de documento: Article

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Compostos de Espiro / Niacinamida / Proteínas Proto-Oncogênicas c-mdm2 / Indóis / Neoplasias Idioma: En Ano de publicação: 2019 Tipo de documento: Article